Thyrocare Technologies Ltd
NSE:THYROCARE

Watchlist Manager
Thyrocare Technologies Ltd Logo
Thyrocare Technologies Ltd
NSE:THYROCARE
Watchlist
Price: 392.65 INR 0.93% Market Closed
Market Cap: ₹62.5B

Thyrocare Technologies Ltd
Total Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Thyrocare Technologies Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Thyrocare Technologies Ltd
NSE:THYROCARE
Total Current Assets
₹3.2B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Dr Agarwal's Eye Hospital Ltd
BSE:526783
Total Current Assets
₹1.3B
CAGR 3-Years
50%
CAGR 5-Years
33%
CAGR 10-Years
17%
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
Total Current Assets
₹15.2B
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
15%
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
Total Current Assets
₹3.1B
CAGR 3-Years
4%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Krsnaa Diagnostics Ltd
NSE:KRSNAA
Total Current Assets
₹4.1B
CAGR 3-Years
7%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Metropolis Healthcare Ltd
NSE:METROPOLIS
Total Current Assets
₹3.5B
CAGR 3-Years
3%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Thyrocare Technologies Ltd
Glance View

Market Cap
62.5B INR
Industry
Health Care

Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.

THYROCARE Intrinsic Value
234.81 INR
Overvaluation 40%
Intrinsic Value
Price ₹392.65

See Also

What is Thyrocare Technologies Ltd's Total Current Assets?
Total Current Assets
3.2B INR

Based on the financial report for Dec 31, 2025, Thyrocare Technologies Ltd's Total Current Assets amounts to 3.2B INR.

What is Thyrocare Technologies Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
11%

Over the last year, the Total Current Assets growth was 32%. The average annual Total Current Assets growth rates for Thyrocare Technologies Ltd have been 10% over the past three years , 11% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett